To the Editor: As originally postulated by Harold Himsworth [1], a reduction in insulin sensitivity in muscle is associated with an increased risk of human type 2 diabetes. Thus, the finding that downregulation of caveolin-1 production leads to a reduction in insulin resistance, which is improved by upregulation of production of this protein as described by Oh et al. [2] , is of considerable interest. Appropriate modulation of caveolin-1 production might be expected to be of benefit for reduction of the risk of type 2 diabetes in humans.
Hypovitaminosis D has been shown to be associated 'dose-wise' with lower insulin sensitivity in humans in cross-sectional studies [3, 4] ; it is also associated with an increased risk of type 2 diabetes both cross-sectionally and prospectively in humans [5] [6] [7] . Caveolin-1 protein is necessary for the rapid non-genomic actions of activated vitamin D [8] . Adequate vitamin D repletion may contribute, therefore, to the maintenance of insulin sensitivity in humans through caveolin-1 modulation. This possibility is supported by the finding of marked insulin resistance and vitamin D resistance in humans with Berardinelli-Seip congenital lipodystrophy, who have a homozygous nonsense caveolin-1 mutation [9] . It would, therefore, be of great interest to know whether activated vitamin D improves insulin sensitivity in the JYD mouse (an ageingdependent non-obese animal model of type 2 diabetes) of Oh et al. [2] and, if so, whether this might be caused by upregulation of caveolin-1 production.
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